CHANGMAO BIO AGM: 100% Shareholder Support Secures 2026 Mandates, Audited 2025 Results Approved

Bulletin Express
May 28

Changmao Biochemical Engineering Company Limited (CHANGMAO BIO) reported full shareholder backing for all matters tabled at its Annual General Meeting (AGM) held on 28 May 2026 in Hong Kong.

• Participation and Voting Out of 529.70 million shares outstanding, 271.00 million shares—approximately 51.16% of issued capital—were voted in person or by proxy. Every resolution received 100% “For” votes, with no votes cast against or abstentions recorded.

• Ordinary Resolutions Passed 1. Approval of the audited consolidated financial statements and accompanying reports for the year ended 31 December 2025. 2. Re-appointment of PricewaterhouseCoopers as international auditor until the next AGM, with the Board authorised to determine remuneration. 3. Re-appointment of PricewaterhouseCoopers Zhong Tian LLP as domestic auditor on the same terms.

• Special Resolutions Passed 1. Authorisation granting the Board a general mandate to allot and issue new shares. 2. Adoption of amended Articles of Association following regulatory approval, with the Board empowered to execute related documentation.

• Independent Scrutiny Cheng & Cheng Limited, Certified Public Accountants, acted as scrutineer, verifying poll results against voting papers provided by the company.

The unanimous outcomes provide CHANGMAO BIO’s Board with renewed auditing arrangements, an enlarged capital issuance mandate, and updated corporate governance documentation for the forthcoming year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10